NMN accumulation after injury and axon degeneration

NMN accumulation after nerve injury

This paper investigated the accumulation of NMN inside injured axons and its relationship to axon degeneration. An axon is the long projection through which a nerve cell transmits signals. The Japanese headline referred to taking NMN, but the experiment should not be read as a clinical study of oral supplement use.

Axon maintenance depends on enzymes including NMNAT2, which uses NMN in NAD+ biosynthesis. After injury, loss of this relatively unstable enzyme can change the balance of metabolites inside the axon.

A result that challenged a simple NAD+ explanation

The researchers investigated whether degeneration could be explained only by the loss of NAD+. Inhibiting NAMPT, an enzyme involved in NMN production, lowered NAD+ but nevertheless protected injured axons and synapses in the experimental setting.

Adding NMN removed that protection. Expression of a bacterial NMN-deamidase enzyme, which reduces NMN accumulation through an alternative reaction, also extended the survival of injured axons. Together, these pharmacological and genetic observations implicated the rise in NMN after loss of NMNAT2.

Wallerian degeneration and enzyme location

The archive discusses Wallerian degeneration, the progressive breakdown of the distal portion of an axon after it is separated from the cell body. It is distinct from, although related to, processes involved in the death of the cell body itself.

Earlier research on protective NMNAT-related proteins showed that enzyme activity and its location inside the cell matter. Moving or stabilizing such activity can influence axon survival. This is more specific than the proposition that increasing a metabolite throughout the body is always beneficial.

The FK866 experiments

In cultured neurons, FK866 was used to inhibit NAMPT. The archive describes experiments in superior cervical ganglion neurons in which NAD+ declined but the timing of treatment around axon injury influenced protection. The effect was not explained simply by stabilization of NMNAT2.

These are mechanistic laboratory experiments involving an investigational pathway manipulation. They are not instructions to use FK866 or to change a person's supplement regimen.

What the paper contributes

The results provide evidence that the balance and location of NAD-related metabolites can be important during nerve injury. They also demonstrate why potentially unfavorable findings must be included when describing NMN research.

The experiment does not, by itself, quantify the risk of ordinary oral NMN use in humans. Conversely, it should not be converted into a claim that NMN protects all nerves. Route, dose, tissue, injury state and the enzymes present all affect interpretation.

Cited paper: A rise in NAD precursor nicotinamide mononucleotide (NMN) after injury promotes axon degeneration. This English edition distinguishes intracellular injury mechanisms from untested claims about oral supplementation.